nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroxyaluminium—VDAC2—prostate gland—urinary bladder cancer	0.0391	0.0751	CbGeAlD
Dihydroxyaluminium—VDAC3—prostate gland—urinary bladder cancer	0.0325	0.0626	CbGeAlD
Dihydroxyaluminium—VDAC1—prostate gland—urinary bladder cancer	0.0309	0.0595	CbGeAlD
Dihydroxyaluminium—VDAC2—epithelium—urinary bladder cancer	0.0287	0.0552	CbGeAlD
Dihydroxyaluminium—VDAC3—seminal vesicle—urinary bladder cancer	0.0275	0.0529	CbGeAlD
Dihydroxyaluminium—VDAC2—renal system—urinary bladder cancer	0.0266	0.0512	CbGeAlD
Dihydroxyaluminium—TNNC1—prostate gland—urinary bladder cancer	0.0265	0.051	CbGeAlD
Dihydroxyaluminium—VDAC1—seminal vesicle—urinary bladder cancer	0.0262	0.0503	CbGeAlD
Dihydroxyaluminium—Venous thrombosis—Carboplatin—urinary bladder cancer	0.0252	0.0525	CcSEcCtD
Dihydroxyaluminium—VDAC3—smooth muscle tissue—urinary bladder cancer	0.023	0.0443	CbGeAlD
Dihydroxyaluminium—VDAC1—epithelium—urinary bladder cancer	0.0227	0.0437	CbGeAlD
Dihydroxyaluminium—VDAC3—renal system—urinary bladder cancer	0.0222	0.0426	CbGeAlD
Dihydroxyaluminium—VDAC1—smooth muscle tissue—urinary bladder cancer	0.0219	0.0421	CbGeAlD
Dihydroxyaluminium—Fluid overload—Carboplatin—urinary bladder cancer	0.0219	0.0455	CcSEcCtD
Dihydroxyaluminium—VDAC3—urethra—urinary bladder cancer	0.0218	0.0419	CbGeAlD
Dihydroxyaluminium—VDAC2—female reproductive system—urinary bladder cancer	0.0213	0.041	CbGeAlD
Dihydroxyaluminium—VDAC1—renal system—urinary bladder cancer	0.0211	0.0406	CbGeAlD
Dihydroxyaluminium—VDAC1—urethra—urinary bladder cancer	0.0207	0.0398	CbGeAlD
Dihydroxyaluminium—VDAC3—female reproductive system—urinary bladder cancer	0.0178	0.0341	CbGeAlD
Dihydroxyaluminium—VDAC1—female reproductive system—urinary bladder cancer	0.0169	0.0325	CbGeAlD
Dihydroxyaluminium—VDAC3—vagina—urinary bladder cancer	0.0161	0.0309	CbGeAlD
Dihydroxyaluminium—Extravasation—Carboplatin—urinary bladder cancer	0.0156	0.0325	CcSEcCtD
Dihydroxyaluminium—VDAC1—vagina—urinary bladder cancer	0.0153	0.0294	CbGeAlD
Dihydroxyaluminium—Diuresis—Cisplatin—urinary bladder cancer	0.0129	0.0268	CcSEcCtD
Dihydroxyaluminium—Haemolysis—Cisplatin—urinary bladder cancer	0.0125	0.0261	CcSEcCtD
Dihydroxyaluminium—VDAC2—lymph node—urinary bladder cancer	0.0125	0.024	CbGeAlD
Dihydroxyaluminium—Blindness transient—Methotrexate—urinary bladder cancer	0.012	0.025	CcSEcCtD
Dihydroxyaluminium—Extravasation—Mitomycin—urinary bladder cancer	0.0116	0.0241	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Carboplatin—urinary bladder cancer	0.0115	0.0239	CcSEcCtD
Dihydroxyaluminium—VDAC3—lymph node—urinary bladder cancer	0.0104	0.02	CbGeAlD
Dihydroxyaluminium—Urinary retention—Valrubicin—urinary bladder cancer	0.0101	0.0211	CcSEcCtD
Dihydroxyaluminium—VDAC1—lymph node—urinary bladder cancer	0.00988	0.019	CbGeAlD
Dihydroxyaluminium—Thrombophlebitis—Mitomycin—urinary bladder cancer	0.00848	0.0177	CcSEcCtD
Dihydroxyaluminium—TNNC1—lymph node—urinary bladder cancer	0.00847	0.0163	CbGeAlD
Dihydroxyaluminium—Encephalopathy—Thiotepa—urinary bladder cancer	0.00792	0.0165	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Cisplatin—urinary bladder cancer	0.00739	0.0154	CcSEcCtD
Dihydroxyaluminium—Encephalopathy—Fluorouracil—urinary bladder cancer	0.00655	0.0137	CcSEcCtD
Dihydroxyaluminium—Fluid overload—Cisplatin—urinary bladder cancer	0.00641	0.0134	CcSEcCtD
Dihydroxyaluminium—Back pain—Valrubicin—urinary bladder cancer	0.00621	0.0129	CcSEcCtD
Dihydroxyaluminium—Extravasation—Thiotepa—urinary bladder cancer	0.00583	0.0121	CcSEcCtD
Dihydroxyaluminium—Extravasation—Gemcitabine—urinary bladder cancer	0.0049	0.0102	CcSEcCtD
Dihydroxyaluminium—Extravasation—Fluorouracil—urinary bladder cancer	0.00482	0.01	CcSEcCtD
Dihydroxyaluminium—Infection—Carboplatin—urinary bladder cancer	0.00482	0.01	CcSEcCtD
Dihydroxyaluminium—Extravasation—Cisplatin—urinary bladder cancer	0.00457	0.00952	CcSEcCtD
Dihydroxyaluminium—Extravasation—Etoposide—urinary bladder cancer	0.00419	0.00872	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Mitomycin—urinary bladder cancer	0.00417	0.00868	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Etoposide—urinary bladder cancer	0.00416	0.00866	CcSEcCtD
Dihydroxyaluminium—Pain—Carboplatin—urinary bladder cancer	0.00415	0.00864	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Valrubicin—urinary bladder cancer	0.00414	0.00862	CcSEcCtD
Dihydroxyaluminium—Coma—Fluorouracil—urinary bladder cancer	0.00384	0.00801	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Carboplatin—urinary bladder cancer	0.00383	0.00799	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Epirubicin—urinary bladder cancer	0.00379	0.0079	CcSEcCtD
Dihydroxyaluminium—Oedema—Mitomycin—urinary bladder cancer	0.00361	0.00752	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Valrubicin—urinary bladder cancer	0.00358	0.00746	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Fluorouracil—urinary bladder cancer	0.00353	0.00735	CcSEcCtD
Dihydroxyaluminium—Urinary retention—Thiotepa—urinary bladder cancer	0.00351	0.00731	CcSEcCtD
Dihydroxyaluminium—Venous thrombosis—Doxorubicin—urinary bladder cancer	0.00351	0.00731	CcSEcCtD
Dihydroxyaluminium—Dizziness—Valrubicin—urinary bladder cancer	0.00346	0.00721	CcSEcCtD
Dihydroxyaluminium—Dehydration—Thiotepa—urinary bladder cancer	0.00343	0.00715	CcSEcCtD
Dihydroxyaluminium—Encephalopathy—Methotrexate—urinary bladder cancer	0.00341	0.0071	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Cisplatin—urinary bladder cancer	0.00336	0.007	CcSEcCtD
Dihydroxyaluminium—Vomiting—Valrubicin—urinary bladder cancer	0.00333	0.00694	CcSEcCtD
Dihydroxyaluminium—Polyuria—Cisplatin—urinary bladder cancer	0.0033	0.00687	CcSEcCtD
Dihydroxyaluminium—Nausea—Valrubicin—urinary bladder cancer	0.00311	0.00648	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Methotrexate—urinary bladder cancer	0.00309	0.00644	CcSEcCtD
Dihydroxyaluminium—Pain—Mitomycin—urinary bladder cancer	0.00308	0.00643	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Etoposide—urinary bladder cancer	0.00308	0.00641	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Cisplatin—urinary bladder cancer	0.00291	0.00605	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Epirubicin—urinary bladder cancer	0.00289	0.00603	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Mitomycin—urinary bladder cancer	0.00285	0.00594	CcSEcCtD
Dihydroxyaluminium—Dehydration—Cisplatin—urinary bladder cancer	0.00269	0.00561	CcSEcCtD
Dihydroxyaluminium—Lung disorder—Doxorubicin—urinary bladder cancer	0.00268	0.00558	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Fluorouracil—urinary bladder cancer	0.00257	0.00536	CcSEcCtD
Dihydroxyaluminium—Extravasation—Methotrexate—urinary bladder cancer	0.00251	0.00522	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Mitomycin—urinary bladder cancer	0.00247	0.00514	CcSEcCtD
Dihydroxyaluminium—Dizziness—Mitomycin—urinary bladder cancer	0.00239	0.00497	CcSEcCtD
Dihydroxyaluminium—Extravasation—Epirubicin—urinary bladder cancer	0.00235	0.00489	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Epirubicin—urinary bladder cancer	0.00233	0.00486	CcSEcCtD
Dihydroxyaluminium—Vomiting—Mitomycin—urinary bladder cancer	0.00229	0.00478	CcSEcCtD
Dihydroxyaluminium—Chills—Thiotepa—urinary bladder cancer	0.00229	0.00477	CcSEcCtD
Dihydroxyaluminium—Extravasation—Doxorubicin—urinary bladder cancer	0.00217	0.00452	CcSEcCtD
Dihydroxyaluminium—Cardiovascular disorder—Doxorubicin—urinary bladder cancer	0.00216	0.00449	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Gemcitabine—urinary bladder cancer	0.00215	0.00449	CcSEcCtD
Dihydroxyaluminium—Back pain—Thiotepa—urinary bladder cancer	0.00215	0.00448	CcSEcCtD
Dihydroxyaluminium—Nausea—Mitomycin—urinary bladder cancer	0.00214	0.00446	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Fluorouracil—urinary bladder cancer	0.00212	0.00441	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Thiotepa—urinary bladder cancer	0.00209	0.00436	CcSEcCtD
Dihydroxyaluminium—Coma—Methotrexate—urinary bladder cancer	0.002	0.00417	CcSEcCtD
Dihydroxyaluminium—Salivary hypersecretion—Epirubicin—urinary bladder cancer	0.00199	0.00414	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Cisplatin—urinary bladder cancer	0.00193	0.00402	CcSEcCtD
Dihydroxyaluminium—Chills—Gemcitabine—urinary bladder cancer	0.00193	0.00402	CcSEcCtD
Dihydroxyaluminium—Convulsion—Thiotepa—urinary bladder cancer	0.00193	0.00401	CcSEcCtD
Dihydroxyaluminium—Coma—Epirubicin—urinary bladder cancer	0.00187	0.0039	CcSEcCtD
Dihydroxyaluminium—Salivary hypersecretion—Doxorubicin—urinary bladder cancer	0.00184	0.00383	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Methotrexate—urinary bladder cancer	0.00183	0.00382	CcSEcCtD
Dihydroxyaluminium—Back pain—Gemcitabine—urinary bladder cancer	0.00181	0.00377	CcSEcCtD
Dihydroxyaluminium—Polyuria—Methotrexate—urinary bladder cancer	0.00181	0.00377	CcSEcCtD
Dihydroxyaluminium—Infection—Thiotepa—urinary bladder cancer	0.0018	0.00376	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Thiotepa—urinary bladder cancer	0.00177	0.00369	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Fluorouracil—urinary bladder cancer	0.00173	0.00361	CcSEcCtD
Dihydroxyaluminium—Coma—Doxorubicin—urinary bladder cancer	0.00173	0.00361	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Epirubicin—urinary bladder cancer	0.00173	0.00359	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Epirubicin—urinary bladder cancer	0.00172	0.00358	CcSEcCtD
Dihydroxyaluminium—Visual disturbance—Methotrexate—urinary bladder cancer	0.00168	0.00349	CcSEcCtD
Dihydroxyaluminium—Chills—Etoposide—urinary bladder cancer	0.00165	0.00343	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Cisplatin—urinary bladder cancer	0.00164	0.00342	CcSEcCtD
Dihydroxyaluminium—Phlebitis—Doxorubicin—urinary bladder cancer	0.0016	0.00333	CcSEcCtD
Dihydroxyaluminium—Convulsion—Fluorouracil—urinary bladder cancer	0.00159	0.00332	CcSEcCtD
Dihydroxyaluminium—Thrombophlebitis—Doxorubicin—urinary bladder cancer	0.00159	0.00331	CcSEcCtD
Dihydroxyaluminium—Pain—Thiotepa—urinary bladder cancer	0.00155	0.00323	CcSEcCtD
Dihydroxyaluminium—Back pain—Etoposide—urinary bladder cancer	0.00154	0.00322	CcSEcCtD
Dihydroxyaluminium—Oedema—Gemcitabine—urinary bladder cancer	0.00153	0.00318	CcSEcCtD
Dihydroxyaluminium—Infection—Gemcitabine—urinary bladder cancer	0.00152	0.00316	CcSEcCtD
Dihydroxyaluminium—Convulsion—Cisplatin—urinary bladder cancer	0.00151	0.00315	CcSEcCtD
Dihydroxyaluminium—Oedema—Fluorouracil—urinary bladder cancer	0.0015	0.00313	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Epirubicin—urinary bladder cancer	0.00149	0.00311	CcSEcCtD
Dihydroxyaluminium—Infection—Fluorouracil—urinary bladder cancer	0.00149	0.00311	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Fluorouracil—urinary bladder cancer	0.00146	0.00305	CcSEcCtD
Dihydroxyaluminium—Urticaria—Thiotepa—urinary bladder cancer	0.00144	0.003	CcSEcCtD
Dihydroxyaluminium—Vertigo—Etoposide—urinary bladder cancer	0.00143	0.00299	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Thiotepa—urinary bladder cancer	0.00143	0.00299	CcSEcCtD
Dihydroxyaluminium—Hypotension—Gemcitabine—urinary bladder cancer	0.00143	0.00297	CcSEcCtD
Dihydroxyaluminium—Oedema—Cisplatin—urinary bladder cancer	0.00142	0.00296	CcSEcCtD
Dihydroxyaluminium—Infection—Cisplatin—urinary bladder cancer	0.00141	0.00294	CcSEcCtD
Dihydroxyaluminium—Hypotension—Fluorouracil—urinary bladder cancer	0.0014	0.00292	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Cisplatin—urinary bladder cancer	0.00139	0.00289	CcSEcCtD
Dihydroxyaluminium—Convulsion—Etoposide—urinary bladder cancer	0.00138	0.00288	CcSEcCtD
Dihydroxyaluminium—Dehydration—Epirubicin—urinary bladder cancer	0.00138	0.00288	CcSEcCtD
Dihydroxyaluminium—Hyponatraemia—Doxorubicin—urinary bladder cancer	0.00138	0.00288	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00134	0.00278	CcSEcCtD
Dihydroxyaluminium—Hypotension—Cisplatin—urinary bladder cancer	0.00133	0.00277	CcSEcCtD
Dihydroxyaluminium—Pain—Gemcitabine—urinary bladder cancer	0.00131	0.00272	CcSEcCtD
Dihydroxyaluminium—Infection—Etoposide—urinary bladder cancer	0.00129	0.0027	CcSEcCtD
Dihydroxyaluminium—Pain—Fluorouracil—urinary bladder cancer	0.00128	0.00267	CcSEcCtD
Dihydroxyaluminium—Dehydration—Doxorubicin—urinary bladder cancer	0.00128	0.00266	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Etoposide—urinary bladder cancer	0.00127	0.00265	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Epirubicin—urinary bladder cancer	0.00125	0.00261	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Thiotepa—urinary bladder cancer	0.00124	0.00259	CcSEcCtD
Dihydroxyaluminium—Hypotension—Etoposide—urinary bladder cancer	0.00122	0.00254	CcSEcCtD
Dihydroxyaluminium—Pain—Cisplatin—urinary bladder cancer	0.00122	0.00253	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00121	0.00251	CcSEcCtD
Dihydroxyaluminium—Dizziness—Thiotepa—urinary bladder cancer	0.0012	0.0025	CcSEcCtD
Dihydroxyaluminium—Urticaria—Fluorouracil—urinary bladder cancer	0.00119	0.00248	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Fluorouracil—urinary bladder cancer	0.00119	0.00247	CcSEcCtD
Dihydroxyaluminium—Angina pectoris—Doxorubicin—urinary bladder cancer	0.00116	0.00241	CcSEcCtD
Dihydroxyaluminium—Vomiting—Thiotepa—urinary bladder cancer	0.00115	0.0024	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Cisplatin—urinary bladder cancer	0.00112	0.00234	CcSEcCtD
Dihydroxyaluminium—Pain—Etoposide—urinary bladder cancer	0.00111	0.00232	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00111	0.0023	CcSEcCtD
Dihydroxyaluminium—Nausea—Thiotepa—urinary bladder cancer	0.00108	0.00225	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Methotrexate—urinary bladder cancer	0.00106	0.00221	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00105	0.00218	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00104	0.00218	CcSEcCtD
Dihydroxyaluminium—Urticaria—Etoposide—urinary bladder cancer	0.00104	0.00216	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Epirubicin—urinary bladder cancer	0.00103	0.00215	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Etoposide—urinary bladder cancer	0.00103	0.00215	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00103	0.00214	CcSEcCtD
Dihydroxyaluminium—Dizziness—Fluorouracil—urinary bladder cancer	0.000992	0.00207	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Epirubicin—urinary bladder cancer	0.000991	0.00206	CcSEcCtD
Dihydroxyaluminium—Chills—Methotrexate—urinary bladder cancer	0.000986	0.00205	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Cisplatin—urinary bladder cancer	0.000973	0.00203	CcSEcCtD
Dihydroxyaluminium—Vomiting—Gemcitabine—urinary bladder cancer	0.00097	0.00202	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Etoposide—urinary bladder cancer	0.00096	0.002	CcSEcCtD
Dihydroxyaluminium—Vomiting—Fluorouracil—urinary bladder cancer	0.000954	0.00199	CcSEcCtD
Dihydroxyaluminium—Rhinitis—Doxorubicin—urinary bladder cancer	0.000954	0.00199	CcSEcCtD
Dihydroxyaluminium—Back pain—Methotrexate—urinary bladder cancer	0.000925	0.00193	CcSEcCtD
Dihydroxyaluminium—Chills—Epirubicin—urinary bladder cancer	0.000923	0.00192	CcSEcCtD
Dihydroxyaluminium—Visual impairment—Doxorubicin—urinary bladder cancer	0.000917	0.00191	CcSEcCtD
Dihydroxyaluminium—Nausea—Gemcitabine—urinary bladder cancer	0.000907	0.00189	CcSEcCtD
Dihydroxyaluminium—Vomiting—Cisplatin—urinary bladder cancer	0.000904	0.00188	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Methotrexate—urinary bladder cancer	0.000901	0.00188	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Etoposide—urinary bladder cancer	0.000892	0.00186	CcSEcCtD
Dihydroxyaluminium—Nausea—Fluorouracil—urinary bladder cancer	0.000891	0.00186	CcSEcCtD
Dihydroxyaluminium—Back pain—Epirubicin—urinary bladder cancer	0.000866	0.0018	CcSEcCtD
Dihydroxyaluminium—Dizziness—Etoposide—urinary bladder cancer	0.000862	0.0018	CcSEcCtD
Dihydroxyaluminium—Vertigo—Methotrexate—urinary bladder cancer	0.000859	0.00179	CcSEcCtD
Dihydroxyaluminium—Chills—Doxorubicin—urinary bladder cancer	0.000854	0.00178	CcSEcCtD
Dihydroxyaluminium—Nausea—Cisplatin—urinary bladder cancer	0.000845	0.00176	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Epirubicin—urinary bladder cancer	0.000844	0.00176	CcSEcCtD
Dihydroxyaluminium—Convulsion—Methotrexate—urinary bladder cancer	0.000829	0.00173	CcSEcCtD
Dihydroxyaluminium—Vomiting—Etoposide—urinary bladder cancer	0.000829	0.00173	CcSEcCtD
Dihydroxyaluminium—Vertigo—Epirubicin—urinary bladder cancer	0.000804	0.00168	CcSEcCtD
Dihydroxyaluminium—Back pain—Doxorubicin—urinary bladder cancer	0.000801	0.00167	CcSEcCtD
Dihydroxyaluminium—Vision blurred—Doxorubicin—urinary bladder cancer	0.000781	0.00163	CcSEcCtD
Dihydroxyaluminium—Convulsion—Epirubicin—urinary bladder cancer	0.000776	0.00162	CcSEcCtD
Dihydroxyaluminium—Infection—Methotrexate—urinary bladder cancer	0.000775	0.00162	CcSEcCtD
Dihydroxyaluminium—Nausea—Etoposide—urinary bladder cancer	0.000774	0.00161	CcSEcCtD
Dihydroxyaluminium—Vertigo—Doxorubicin—urinary bladder cancer	0.000744	0.00155	CcSEcCtD
Dihydroxyaluminium—Oedema—Epirubicin—urinary bladder cancer	0.000731	0.00152	CcSEcCtD
Dihydroxyaluminium—Hypotension—Methotrexate—urinary bladder cancer	0.000729	0.00152	CcSEcCtD
Dihydroxyaluminium—Infection—Epirubicin—urinary bladder cancer	0.000726	0.00151	CcSEcCtD
Dihydroxyaluminium—Convulsion—Doxorubicin—urinary bladder cancer	0.000718	0.0015	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Epirubicin—urinary bladder cancer	0.000713	0.00149	CcSEcCtD
Dihydroxyaluminium—Hypotension—Epirubicin—urinary bladder cancer	0.000683	0.00142	CcSEcCtD
Dihydroxyaluminium—Oedema—Doxorubicin—urinary bladder cancer	0.000676	0.00141	CcSEcCtD
Dihydroxyaluminium—Infection—Doxorubicin—urinary bladder cancer	0.000671	0.0014	CcSEcCtD
Dihydroxyaluminium—Pain—Methotrexate—urinary bladder cancer	0.000668	0.00139	CcSEcCtD
Dihydroxyaluminium—Tachycardia—Doxorubicin—urinary bladder cancer	0.00066	0.00137	CcSEcCtD
Dihydroxyaluminium—Hypotension—Doxorubicin—urinary bladder cancer	0.000632	0.00132	CcSEcCtD
Dihydroxyaluminium—Pain—Epirubicin—urinary bladder cancer	0.000625	0.0013	CcSEcCtD
Dihydroxyaluminium—Urticaria—Methotrexate—urinary bladder cancer	0.00062	0.00129	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Methotrexate—urinary bladder cancer	0.000617	0.00129	CcSEcCtD
Dihydroxyaluminium—Urticaria—Epirubicin—urinary bladder cancer	0.00058	0.00121	CcSEcCtD
Dihydroxyaluminium—Pain—Doxorubicin—urinary bladder cancer	0.000578	0.0012	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Epirubicin—urinary bladder cancer	0.000577	0.0012	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000575	0.0012	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000538	0.00112	CcSEcCtD
Dihydroxyaluminium—Urticaria—Doxorubicin—urinary bladder cancer	0.000537	0.00112	CcSEcCtD
Dihydroxyaluminium—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000534	0.00111	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Methotrexate—urinary bladder cancer	0.000534	0.00111	CcSEcCtD
Dihydroxyaluminium—Dizziness—Methotrexate—urinary bladder cancer	0.000516	0.00108	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Epirubicin—urinary bladder cancer	0.0005	0.00104	CcSEcCtD
Dihydroxyaluminium—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000498	0.00104	CcSEcCtD
Dihydroxyaluminium—Vomiting—Methotrexate—urinary bladder cancer	0.000496	0.00103	CcSEcCtD
Dihydroxyaluminium—Dizziness—Epirubicin—urinary bladder cancer	0.000483	0.00101	CcSEcCtD
Dihydroxyaluminium—Vomiting—Epirubicin—urinary bladder cancer	0.000464	0.000968	CcSEcCtD
Dihydroxyaluminium—Nausea—Methotrexate—urinary bladder cancer	0.000464	0.000966	CcSEcCtD
Dihydroxyaluminium—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000462	0.000964	CcSEcCtD
Dihydroxyaluminium—Dizziness—Doxorubicin—urinary bladder cancer	0.000447	0.000931	CcSEcCtD
Dihydroxyaluminium—Nausea—Epirubicin—urinary bladder cancer	0.000434	0.000904	CcSEcCtD
Dihydroxyaluminium—Vomiting—Doxorubicin—urinary bladder cancer	0.00043	0.000895	CcSEcCtD
Dihydroxyaluminium—Nausea—Doxorubicin—urinary bladder cancer	0.000401	0.000836	CcSEcCtD
